EUVIMEDEUVIMED entdecken
Open Access

Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort

Jaehyun Lim iD, Soongu Kwak iD, You-Jung Choi iD, Tae-Min Rhee, Chan Soon Park iD, Bongseong Kim iD, Kyung-Do Han, Heesun Lee iD, Jun-Bean Park iD, Yong-Jin Kim, Hyun-Jung Lee iD, Hyung-Kwan Kim iD

Journal of the American Heart Association · 06.02.2024 · 13 (3)

DOI: 10.1161/jaha.123.030552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 06.02.2024. Verfasst von Jaehyun Lim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Seoul National University Hospital Seoul Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Atrial Fibrillation, Glucosides. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meta‐analyses of large clinical trials investigating SGLT2 (sodium‐glucose cotransporter‐2) inhibitors have suggested their protective effects against atrial fibrillation in patients with type 2 diabetes. However, the results were predominantly driven from trials involving dapagliflozin. Methods and Results We used a nationwide, population‐based cohort of patients with type 2 diabetes who initiated either dapagliflozin or empagliflozin between May 2016 and December 2018. An active‐comparator, new‐user design was used, and the 2 groups of patients were matched using propensity scores. The primary outcome was incident nonvalvular atrial fibrillation, which was analyzed using both the main intention‐to‐treat and sensitivity analysis that censored patients who skipped their medications for ≥30 days. Men ≥55 years of age and women ≥60 years of age with ≥1 traditional risk factor or those with established cardiovascular disease were categorized as high cardiovascular risk group. Patients not included in the high‐risk group were categorized as low risk. After 1:1 propensity‐score matching, a total of 137 928 patients (mean age, 55 years; 58% men) were included and followed up for 2.2±0.6 years. The risk of incident atrial fibrillation was significantly lower in the dapagliflozin group in both the main (hazard ratio [HR], 0.885 [95% CI, 0.789–0.992]) and sensitivity analyses (HR, 0.835 [95% CI, 0.719–0.970]). Notably, this was consistent in both the low and high cardiovascular risk groups. There was no effect modification by age, sex, body mass index, duration of diabetes, or renal function.

Conclusions

This real‐world, population‐based study demonstrates that patients with type 2 diabetes using dapagliflozin may have a lower risk of developing nonvalvular atrial fibrillation than those using empagliflozin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsAtrial FibrillationGlucosidesMaleHumansFemaleMiddle AgedBenzhydryl CompoundsRisk Factors

Stichwörter der Autor:innen

atrial fibrillationdapagliflozinempagliflozinsodium‐glucose cotransporter‐2 inhibitortype 2 diabetes

Substanzen

dapagliflozinempagliflozinSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Department of Internal Medicine Seoul National University Hospital Seoul Republic of Korea.
  • Department of Internal Medicine Seoul National University College of Medicine Seoul Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine Korea University College of Medicine Seoul Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine Seoul National University Hospital Healthcare System Gangnam Center Seoul Republic of Korea.
  • Department of Statistics and Actuarial Science Soongsil University Seoul Republic of Korea.
  • Division of Cardiology Severance Hospital, Yonsei University College of Medicine Seoul Republic of Korea.

ORCID-Profile: Jaehyun Lim, Soongu Kwak, You-Jung Choi, Chan Soon Park, Bongseong Kim, Heesun Lee, Jun-Bean Park, Hyun-Jung Lee, Hyung-Kwan Kim

Zitieren

APA

Lim, J., Kwak, S., Choi, Y. J., Rhee, T. M., Park, C. S., Kim, B., Han, K. D., Lee, H., Park, J. B., Kim, Y. J., Lee, H. J., & Kim, H. K. (2024). Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort. Journal of the American Heart Association, 13(3). https://doi.org/10.1161/jaha.123.030552

Vancouver

Lim J, Kwak S, Choi YJ, Rhee TM, Park CS, Kim B, et al. Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort. Journal of the American Heart Association. 2024;13(3). doi:10.1161/jaha.123.030552

BibTeX
@article{Lim2024,
  author = {Lim, Jaehyun and Kwak, Soongu and Choi, You-Jung and Rhee, Tae-Min and Park, Chan Soon and Kim, Bongseong and Han, Kyung-Do and Lee, Heesun and Park, Jun-Bean and Kim, Yong-Jin and Lee, Hyun-Jung and Kim, Hyung-Kwan},
  title = {Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {3},
  doi = {10.1161/jaha.123.030552}
}
Kostenlos starten →